KRAS and pancreatic neoplasm: In 2019, Lentsch et al. found that efficient KO of c.35G > A (p.G12D) Kras mutation in human pancreatic cancer cell lines SUIT-2 and Panc-1 and mouse cell lines TB32047 is possible [180].